[Longterm treatment of POAD with anticoagulants and platelet inhibitors after endovascular procedures and vascular surgery: what is evidence based?].
Platelet inhibitors and anticoagulants are used in the longterm treatment after successful infrainguinal bypass grafts as well as endovascular revascularisation procedures. However, evidence of the usefulness of these therapies is limited with respect to efficiency (patency rate, mortality) and safety (bleeding tendency) concerning these indications. Sufficient data are only available for acetylsalicylic acid treatment after implantation of prosthetic bypass grafts, the data basis for the use of antithrombotic medication in venous bypass grafts or following successful balloon angioplasty with or without stent implantation is, however, inconclusive. The recommendation for lifelong therapy with acetylsalicylic acid after infrainguinal bypass surgery and endovascular treatment is based mainly on the concept of prophylactic treatment of manifest atherosclerotic disease.
Landgraf
H
H
Klinik für Innere Medizin--Angiologie und Hämostaseologie, Zentrum für Gefässmedizin, Vivantes-Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin. helmut.landgraf@vivantes.de
D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D001026:Coronary Artery Bypass; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011184:Postoperative Period; D014652:Vascular Diseases / Q000188:drug therapy* / Q000628:therapy*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D006493:Heparin